SARS News and Research

RSS

Acute myocarditis extremely rare after COVID mRNA vaccination in adults

Now, a new study published in the journal JAMA Internal Medicine evaluated the incidence of acute myocarditis and clinical outcomes among adults who received the mRNA vaccine in an integrated health care system in the United States.

5 Oct 2021

Neonatal outcomes of preterm infants born during COVID lockdowns in Melbourne, Australia

A team of researchers from Australian institutes examined the consequences of community-wide lockdowns on neonatal outcomes of preterm infants, with a secondary focus on the underlying rates of systemic inflammation in infants and mothers around the time of birth.

5 Oct 2021

Research highlights challenges in utilizing Ct data to guide COVID-19 clinical planning

In a new study, a collaboration of researchers from various institutes described the natural history of SARS-CoV-2 testing, which includes Ct values among patients who had tested positive multiple times, prior to the emergence of VOCs in the vaccine roll-out. In addition, the authors analyze the timescale of positivity and clinical features of the population of patients with prolonged SARS-CoV-2 positivity.

5 Oct 2021

SARS-CoV-2 variants of concern more virulent than the native strain of the virus

A large study from Ontario confirms that SARS-CoV-2 variants of concern (VOCs), especially the Delta variant, are more virulent than the native strain of the virus, increasing people's risk of hospitalization, admission to the intensive care unit (ICU) and death due to COVID-19.

5 Oct 2021

A review of COVID data reporting in Africa

An international team of scientists has recently investigated how African countries report and share data related to the Coronavirus disease 2019 (COVID-19) pandemic. They have found that African countries use distinct reporting systems that include social media posts, website updates, situation reports, press releases, and online dashboards. A detailed report of the findings is currently available on the medRxiv* preprint server.

5 Oct 2021

Cysteamine inhibits SARS-CoV-2 variants of concern in vitro

Researchers in the United States have shown that a compound currently used to treat cystinosis exhibits broad antiviral activity against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 Oct 2021

Plasmid DNA vaccines induce effective antibody responses against SARS-CoV-2 in mice

Researchers in the United States and China have developed plasmid DNA immunogens that induce effective antibody responses in mice against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 Oct 2021

AstraZeneca COVID-19 vaccine safe and effective in phase 3 U.S., Chile, and Peru trial

A new study reports on the results of phase III clinical trial on the safety and efficacy of the AstraZeneca-Oxford COVID-19 vaccine.

5 Oct 2021

A possible protective genetic polymorphism in COVID-19

A new study discusses the role of a mucin gene enhancer on the clinical phenotype of the COVID-19.

5 Oct 2021

Anti-nucleocapsid SARS-Cov-2 antibodies wane over time in long-term care facilities

A new study shows that up to a third of survivors in LTCFs were infected during the first year after infection.

5 Oct 2021

SARS-CoV-2 beta variant elicits variant specific and cross-reactive antibodies

One recent study assessed the serum of Beta variant infected patients to determine whether major non-VOC antibodies could neutralize this virus.

5 Oct 2021

Emergence and evolution of endemic and emerging coronavirus diversity in humans and animals

A study aimed to understand the evolutionary and epidemiology dynamics of coronavirus diversity in animals, humans, and wildlife at ecosystem interfaces.

5 Oct 2021

Connection between aerosol transmission and COVID-19 dynamics

A simulation study explored event-level overdispersion of SARS-Cov-2 spread, utilizing real-world inputs from a large number of social gatherings.

5 Oct 2021

The role of ZBP1 in promoting SARS-CoV-2-induced cytokine expression

A new study reported that the ZBP1-induced inflammatory signaling pathway is dependent on ubiquitination and RIPK3’s scaffolding ability, independent of cell death.

5 Oct 2021

Anti-CD20 therapy patients can develop immune responses after SARS-CoV-2 vaccination

A new systematic review and meta-analysis focused on the humoral and cell-mediated immune responses after COVID-19 vaccination in patients undergoing anti-CD20 antibodies treatment.

5 Oct 2021

Humoral responses to SARS-CoV-2 are detectable through saliva, scientists find

Your saliva may be able to tell you if you’ve developed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, suggests a new medRxiv* preprint study. In immunocompromised groups, salivary Immunoglobulin G (IgG) antibody levels were associated with IgG titers in blood serum 3 to 4 weeks after mRNA vaccination.

5 Oct 2021

Study suggests shingles vaccine reduces the risk for COVID-19

People who get the shingles vaccine may have a lower risk of being diagnosed and hospitalized with coronavirus disease 2019 (COVID-19), according to a new medRxiv* preprint study. In about 150,000 people over the age of 50, vaccination for shingles was associated with a 32% reduced risk of severe COVID-19 infection.

5 Oct 2021

New study underscores the importance of improving COVID-19 vaccination rates worldwide

Two doses of Pfizer-BioNTech (BNT162b2) are 90% effective against COVID-19 hospitalizations for all variants, including delta, for at least six months, confirms a new study from Kaiser Permanente and Pfizer published in The Lancet.

5 Oct 2021

SARS-CoV-2 mRNA vaccines elicit higher levels of antibodies compared to natural infection

Researchers from the US recently characterized the scale and specificity of SARS-CoV-2 spike-reactive antibodies from 23 participants who received SARS-CoV-2 mRNA vaccines and 10 acutely infected health care workers. They found that primary mRNA vaccination and infection elicited S1- and S2-reactive antibodies, while secondary mRNA vaccination elicited mostly S1 antibodies.

4 Oct 2021

What makes SARS-CoV-2 variants more virulent?

Researchers in the Republic of Korea have conducted a study of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – that could help to inform further studies investigating the increased virulence of variants of concern and interest.

4 Oct 2021

SARS News and Research

Acute myocarditis extremely rare after COVID mRNA vaccination in adults

Neonatal outcomes of preterm infants born during COVID lockdowns in Melbourne, Australia

Research highlights challenges in utilizing Ct data to guide COVID-19 clinical planning

SARS-CoV-2 variants of concern more virulent than the native strain of the virus

A review of COVID data reporting in Africa

Cysteamine inhibits SARS-CoV-2 variants of concern in vitro

Plasmid DNA vaccines induce effective antibody responses against SARS-CoV-2 in mice

AstraZeneca COVID-19 vaccine safe and effective in phase 3 U.S., Chile, and Peru trial

A possible protective genetic polymorphism in COVID-19

Anti-nucleocapsid SARS-Cov-2 antibodies wane over time in long-term care facilities

SARS-CoV-2 beta variant elicits variant specific and cross-reactive antibodies

Emergence and evolution of endemic and emerging coronavirus diversity in humans and animals

Connection between aerosol transmission and COVID-19 dynamics

The role of ZBP1 in promoting SARS-CoV-2-induced cytokine expression

Anti-CD20 therapy patients can develop immune responses after SARS-CoV-2 vaccination

Humoral responses to SARS-CoV-2 are detectable through saliva, scientists find

Study suggests shingles vaccine reduces the risk for COVID-19

New study underscores the importance of improving COVID-19 vaccination rates worldwide

SARS-CoV-2 mRNA vaccines elicit higher levels of antibodies compared to natural infection

What makes SARS-CoV-2 variants more virulent?

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News